SCHEMBL308624

SCHEMBL308624

CCOC(=O)c1cc(OC)c(C)c([N+](=O)[O-])c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
HSD17B2 P37059 1/20 0.51
NPC1 O15118 2/20 0.51
ALDH1A1 P00352 10/20 0.51
MAPT P10636 5/20 0.51
RAB9A P51151 3/20 0.51
PKM P14618 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
PTGER4 P35408 1/20 0.51
LMNA P02545 4/20 0.50
POLB P06746 3/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 4/20 0.48
HTT P42858 1/20 0.48
ESR1 P03372 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6815909 0.88 KMT2A (0.59) KMT2ANPC1ALDH1A1MAPTRAB9A
SCHEMBL309910 0.87 ESR1 (0.56) KMT2AHSD17B2NPC1ALDH1A1MAPT
SCHEMBL2896738 0.87 MAPT (0.51) KMT2AALDH1A1MAPTLMNAPOLB
SCHEMBL25255894 0.86 KMT2A (0.50) KMT2AHSD17B2NPC1ALDH1A1MAPT
SCHEMBL5925578 0.83 HSD17B2 (0.62) KMT2AHSD17B2NPC1ALDH1A1MAPT
SCHEMBL28483458 0.83 ALDH1A1 (0.63) KMT2AHSD17B2NPC1ALDH1A1MAPT
SCHEMBL3838309 0.83 KMT2A (0.53) KMT2AHSD17B2NPC1ALDH1A1MAPT
SCHEMBL2896874 0.82 TPMT (0.59) KMT2AALDH1A1MAPTPKMLMNA
SCHEMBL308928 0.82 KMT2A (0.46) KMT2AHSD17B2NPC1ALDH1A1MAPT
SCHEMBL450492 0.81 NPC1 (0.59) KMT2ANPC1ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111406-B1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK SHARP & DOHME (US) 2012-10-24 EP disclosed
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
EP-2111406-A1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS Merck & Co., Inc. (US) 2009-10-28 EP disclosed
WO-2008088688-A1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK & CO., INC. (US) 2008-07-24 WO disclosed
WO-2008088689-A1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK & CO., INC. (US) 2008-07-24 WO disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 KMT2A 3886/4885HSD17B2 1192/4885NPC1 3402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.